Business
Alps Group Inc Announces Potential Pipeline Expansion Beyond CELESOME(+) Following Publication of Nebulized Human Umbilical Cord Mesenchymal Stem Cell Exosome Therapy
KUALA LUMPUR, Malaysia, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (the “Company” or “Alps Group”), the parent company of Alps Life Sciences Inc. (“Alps Holdco”), a fully integrated biotechnology research and healthcare platform specializing in predictive, preventive, and precision medicine, today announced a potential expansion of its exosome-related pipeline beyond its previously disclosed CELESOME(+) program. The announcement follows the publication of a preliminary retrospective clinic
About this update from Alps Group Inc
[{"type":"image","alt":"Alps Group Inc","displaySize":"","headline":null,"caption":"Alps Group Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":135,"url":"https://media.zenfs.com/en/globenewswire.com/1780d61c1360908512f85687434e2349"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/AXZISgc2pcaNaKgr0DMS0g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE4OTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/1780d61c1360908512f85687434e2349","width":300,"height":135}},"lazy":false},{"type":"text","content":"KUALA LUMPUR, Malaysia, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (the “Company” or “Alps Group”), the parent company of Alps Life Sciences Inc. (“Alps Holdco”), a fully integrated biotechnology research and healthcare platform specializing in predictive, preventive, and precision medicine, today announced a potential expansion of its exosome-related pipeline beyond its previously disclosed CELESOME(+) program. The announcement follows the publication of a preliminary retrospective clinical case series in SAGE Open Medical Case Reports describing nebulized human umbilical cord mesenchymal stem cell (“hUCMSC”) derived exosome in patient with asthma and/or chronic obstructive pulmonary disease (“COPD“). The clinical case series study was registered with the National Medical Research Register, Ministry of Health Malaysia (NMRR ID-25-00600-F4A).","length":860,"tagName":"p"},{"type":"text","content":"The Company has previously disclosed development activities relating to exosome-infused candidates under the CELESOME(+) program. Building on technical experience developed in connection with exosome isolation, handling, and characterization activities described under CELESOME(+), the published report describes observational findings from an investigational, retrospective case series involving nebulized administration to the lungs.","length":435,"tagName":"p"},{"type":"text","content":"Asthma and COPD represent substantial global disease burdens, affecting approximately 260 million (BMJ Open Respiratory Research, Volume 12, Issue 1, 2025) and 400 million (Montes de Oca et al., 2025) individuals worldwide, respectively. Current standard therapies largely focus on symptom management. The Company believes that the reported observations may create an opportunity for nebulized human umbilical cord mesenchymal stem cell‑derive...